Monthly Archives: May 2014

Mrsa | MRSA Isn't The Real Problem With E-Cigs

It’s early, but it sure looks as if the e-cigarette is going to turn out to be every bit as odious as its forebear, the paper and tobacco cigarette.Yet in a wondrous twirl of Don Draper magic, the e-cigarette has positioned itself as the St. Patrick of the 21st century, driving a carton of menthols out of our lives instead of snakes. Ad blitz aside, the e-cig is a problematic, likely toxic ,    .. more …

Facebook Twitter Email

Mrsa Treatment | Antibiotic Resistance Giving Killer Diseases Free Rein: WHO

Geneva (AFP) – The rise of superbugs, stoked by misuse of antibiotics and shoddy hospital hygiene, is enabling long-treatable diseases to once again become killers, the World Health Organization warned on Wednesday.In a hard-hitting study of antimicrobial resistance — when bacteria adapt so that existing drugs no longer beat them — the UN health agency said the issue was a global emergency and    .. more …

Facebook Twitter Email

Flesh Eating Bacteria | Seattle Boy Survives Flesh-eating Bacteria

A 13-year-old boy in Seattle has just been released from a hospital after surviving the ravages of a flesh-eating bacteria. CBS affiliate KIRO-TV reports Trey Lauren spent three weeks at Seattle Children’s Hospital while an aggressive bacteria ate at his leg from the inside. The infection started shortly after Lauren cut his leg with a nail and received six stitches. Five hours later his leg was    .. more …

Facebook Twitter Email

Mrsa | Despite Generic Vancomycin's Continued Dominance Of The MRSA Market, Branded Agents Cubicin And Zyvox Emerge As ...

BURLINGTON, Mass., May 6, 2014 /PRNewswire/ –Decision Resources Group finds that overall, infectious disease (ID) specialists and non-ID physicians (critical care and internal medicine specialists) prefer the branded agents Cubist’s Cubicin (daptomycin) and Pfizer’s Zyvox (linezolid), respectively, when treating methicillin-resistant Staphylococcus aureus (MRSA) infections in the hospital. Nearly    .. more …

Facebook Twitter Email